King's College London

Research portal

Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial

Research output: Contribution to journalArticlepeer-review

Laura L Oakley, Moji Awogbade, Sarah Brien, Annette Briley, Maria Chorozoglou, Emma Drasar, Jemma Johns, Elizabeth Rhodes, Vicky Robinson, Paul Seed, Joseph Sharif, Claire Singh, Paul Telfer, Hilary Thompson, Ingrid Watt-Coote, Jo Howard, Eugene Oteng-Ntim

Original languageEnglish
Article number347
Pages (from-to)347
Issue number1
Published20 Apr 2020


  • Oakley_2020_Prophylactic_blood_tranfusons_in_SCD_pregnancies(TAPS-2_prptocol)

    Oakley_2020_Prophylactic_blood_tranfusons_in_SCD_pregnancies_TAPS_2_prptocol_.pdf, 0.99 MB, application/pdf

    Uploaded date:28 Apr 2020

    Version:Final published version

    Licence:CC BY-SA

    © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
    which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
    appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
    changes were made. The images or other third party material in this article are included in the article's Creative Commons
    licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
    licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
    permission directly from the copyright holder.

King's Authors


BACKGROUND: Pregnancies in women with sickle cell disease (SCD) are associated with a higher risk of sickle and pregnancy complications. Limited options exist for treating SCD during pregnancy. Serial prophylactic exchange blood transfusion (SPEBT) has been shown to be effective in treating SCD outside pregnancy, but evidence is lacking regarding its use during pregnancy. The aim of this study is to assess the feasibility and acceptability of conducting a future phase 3 randomised controlled trial (RCT) to establish the clinical and cost effectiveness of SPEBT in pregnant women with SCD.

METHODS: The study is an individually randomised, two-arm, feasibility trial with embedded qualitative and health economic studies. Fifty women, 18 years of age and older, with SCD and a singleton pregnancy at ≤ 18 weeks' gestation will be recruited from six hospitals in England. Randomisation will be conducted using a secure online database and minimised by centre, SCD genotype and maternal age. Women allocated to the intervention arm will receive SPEBT commencing at ≤ 18 weeks' gestation, performed using automated erythrocytapheresis every 6-10 weeks until the end of pregnancy, aiming to maintain HbS% or combined HbS/HbC% below 30%. Women in the standard care arm will only receive transfusion when clinically indicated. The primary outcome will be the recruitment rate. Additional endpoints include reasons for refusal to participate, attrition rate, protocol adherence, and maternal and neonatal outcomes. Women will be monitored throughout pregnancy to assess maternal, sickle, and foetal complications. Detailed information about adverse events (including hospital admission) and birth outcomes will be extracted from medical records and via interview at 6 weeks postpartum. An embedded qualitative study will consist of interviews with (a) 15-25 trial participants to assess experiences and acceptability, (b) 5-15 women who decline to participate to identify barriers to recruitment and (c) 15-20 clinical staff to explore fidelity and acceptability. A health economic study will inform a future cost effectiveness and cost-utility analysis.

DISCUSSION: This feasibility study aims to rigorously evaluate SPEBT as a treatment for SCD in pregnancy and its impact on maternal and infant outcomes.

TRIAL REGISTRATION: NIH registry (, registration number NCT03975894 (registered 05/06/19); ISRCTN (, registration number ISRCTN52684446 (retrospectively registered 02/08/19).

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454